Stent selection to minimize the risk of stent thrombosis

Current Opinion in Cardiology

Volumn 29, Issue 6, 2014, Pages 578-585

  Palmerini, Tullio ^a   Biondi Zoccai, Giuseppe ^b   Stone, Gregg W ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Department of Medicine   (United States)

Author keywords

Drug eluting stents; Meta analysis; Stent thrombosis

Indexed keywords

CHROMIUM; COBALT; EVEROLIMUS; POLYMER;

BARE METAL STENT; BIODEGRADABLE IMPLANT; DEVICE SAFETY; DRUG ELUTING CORONARY STENT; HUMAN; MATERIAL COATING; MEDICAL TECHNOLOGY; META ANALYSIS; PRIORITY JOURNAL; REVIEW; STENT THROMBOSIS; SYSTEMATIC REVIEW; CORONARY THROMBOSIS; GRAFT OCCLUSION, VASCULAR; MYOCARDIAL ISCHEMIA; PROCEDURES; PROSTHESIS; RISK ASSESSMENT; STENT;

CORONARY THROMBOSIS; GRAFT OCCLUSION, VASCULAR; HUMANS; MYOCARDIAL ISCHEMIA; PROSTHESIS DESIGN; RISK ASSESSMENT; STENTS;

EID: 84927786122     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000102     Document Type: Review

References (45)

1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-1323.
2. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221-231.
3. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297:159-168.
4. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48:2584-2591.
5. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356:998-1008.
6. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48:193-202.
7. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109:701-705.
8. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57:1314-1322.
9. Palmerini T, Dangas G, Mehran R, et al. Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial. Circ Cardiovasc Interv 2011; 4:577-584.
10. Raber L, Kelbaek H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012; 308:777-787.
11. Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus baremetal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012; 380:1482-1490.
12. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxeleluting stents in coronary artery disease.NEngl J Med 2010; 362:1663-1674.
13. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363:136-146.
14. Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, noninferiority trial. Lancet 2013; 381:651-660.
15. Taniwaki M, Stefanini GG, Silber S, et al. Four year clinical outcomes and predictors of repeat revascularization in patients treated with new generation drug-eluting stents in the RESOLUTE All Comers Randomized Trial. J Am Coll Cardiol 2014; 63:1617-1625.
16. Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012; 380:1396-1405.
17. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012; 125:2873-2891.
18. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drugeluting and bare-metal stents: evidence from a comprehensive network metaanalysis. Lancet 2012; 379:1393-1402.
19. Palmerini T, Kirtane AJ, Serruys PW, et al. Stent thrombosis with everolimuseluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012; 5:357-364.
20. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with drugeluting and bare metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2013; 62:496-504.
21. Chin-Quee SL, Hsu SH, Nguyen-Ehrenreich KL, et al. Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings. Biomaterials 2009; 31:648-657.
22. Kolandaivelu K, Swaminathan R, Gibson WJ,et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011; 123:1400-1409.
23. Aslan JE, Tormoen GW, Loren CP, et al. S6K1 and mTOR regulate Rac1- driven platelet activation and aggregation. Blood 2011; 118:3129-3136.
24. Weyrich AS, Denis MM, Schwertz H, et al. mTOR-dependent synthesis of Bcl- 3 controls the retraction of fibrin clots by activated human platelets. Blood 2007; 109:1975-1983.
25. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and baremetal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2014; 63:299-307.
26. Chevalier B, Serruys PW, Silber S, et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus(R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention 2007; 2:426-434.
27. Chevalier B, Silber S, Park SJ, et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial - phase 2. Circ Cardiovasc Interv 2009; 2:188-195.
28. Christiansen EH, Jensen LO, Thayssen P, et al. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised noninferiority trial. Lancet 2013; 381:661-669.
29. Kadota K, Muramatsu T, Iwabuchi M, et al. Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. Catheter Cardiovasc Interv 2012; 80:789-796.
30. Natsuaki M, Kozuma K, Morimoto T, et al. Biodegradable polymer biolimuseluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol 2013; 62:181-190.
31. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised noninferiority trial. Lancet 2008; 372:1163-1173.
32. Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drugeluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012; 33:1214-1222.
33. Mehilli J, Byrne RA, Wieczorek A, et al. Randomized trial of three rapamycineluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008; 29:1975-1982.
34. Byrne RA, Kastrati A, Kufner S, et al. Randomized, noninferiority trial of three limus agent-eluting stents with different polymer coatings: the intracoronary stenting and angiographic results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009; 30:2441-2449.
35. Windecker S, Witzenbichler B, Stangl K, et al. Safety and clinical performance of the drug eluting orsiro stent in the treatment of Subjects With Single De Novo Coronary Artery Lesions II (BIOFLOW II) TCT. San Francisco; 2013; http://www.tctmd.com/show.aspx?id=122906. [Accessed May 2014]
36. Meredith IT, Verheye S, Dubois CL, et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymercoated, everolimus-eluting coronary stent. J Am Coll Cardiol 2012; 59:1362-1370.
37. Bangalore S, Toklu B, Amoroso N, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ 2013; 347:f6625.
38. Kang SH, Park KW, Kang DY, et al. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J 2014; 35:1147-1158.
39. Navarese EP, Tandjung K, Claessen B, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ 2013; 347:f6530.
40. Kang WC, Ahn T, Lee K, et al. Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. EuroIntervention 2011; 7:936-943.
41. Kirtane A, Silber S, Neumann F, et al. The relationship between short and longterm antiplatelet therapy use and stent thrombosis following percutaneous coronary intervention with resolute zotarolimus-eluting stent. J Am Coll Cardiol 2013; 61:1.
42. Palmerini T. Difficult decisions with dual antiplatelet therapy: DES, STEMI, unplanned treatment interruption. EuroPCR Paris 2012; http://www.pcronli ne.com/Lectures/2012/How-would-I-treat69. [Accessed May 2014]
43. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503-1516.
44. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367:2375-2384.
45. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with threevessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381:629-638.